Experts Tout Value-Based Contracts, RWE, Patent Reform As Pricing Fixes

By Beth Wang / June 15, 2017 at 9:03 PM
Academics and policy experts said that value-based contracts, real-world evidence and drug repurposing for off-patent and on-patent drugs could help to spur competition and lower drug prices. One expert also discussed the negative effect that President Donald Trump's proposal to increase FDA user fees would have on the generic drug industry while a former senator said the agency has plenty of money and simply needs a culture change to institute new approval policies. The experts spoke at a drug pricing...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.